All your MA & HTA needs in one place.

About us

Find out more about our history, values and Team.
Explore

Offer

See how we turn clinical data into market access strategies.
Explore

Publications

Read our latest publications.
Explore

Team

MAHTA is first and foremost about people who are dedicated to their work and constantly improving their knowledge, skills and competence.

Meet our team

Partnership

The reason for our immense pride, but also the measurable effect of our daily work, is increased access to effective forms of treatment and improve the quality of life of patients worldwide.

Explore

Bespoke solutions

We support the companies we work with at all stages of the reimbursement process. We offer knowledge, experience and a professional, flexible approach so that the solutions we propose are appropriate, effective and efficient.

Explore

in numbers

400

Over 400

successfully completed

reimbursement processes.

covering HTA.

40

Cooperation with over

40 renowned

specialists from various

areas of expertise.

50

Over 50 international processes successfully implemented.

News

Wishing you peaceful and joyful holidays!

Dear Friends, We are wishing you a peaceful and joyful Holiday Season and success in your daily endeavors. With best regards, MAHTA Team
Explore

World EPA Congress, Amsterdam

We are excited to share that the MAHTA Team will be participating in the World EPA Congress taking place on 3–4 March 2026 in Amsterdam.
Explore

Cost-effectiveness of pasireotide long-acting release in acromegaly: a systematic literature review and methodology assessment

We are excited to share the latest manuscript published in the Journal of Medical Economics, developed by the MAHTA Intl. Team in cooperation with Professor Gilis-Januszewska and Recordati Rare Diseases
Explore
Other news

Publications

Cost-Utility Analysis of Linzagolix 200 mg Plus Add-back Therapy (Linzagolix+ABT) for Symptomatic Treatment of Endometriosis

Binowski G., Paćkowska A. , Marciniak A., Cottrell R., Currell S., Lawrence A., Richard L., Grainger J.
Open

Indirect Treatment Comparison of Biochemical Control Between Pasireotide Long-Acting Release and Pegvisomant as Second-Line Therapies for Acromegaly, Based on Real-World Evidence

Binowski G., Kossi S., Bronikowska M., Paćkowska A., Delgado R., Gueron B., Schmidt F., Chiloiro S
Open

Cost Comparison of Symptom Treatment in Atopic Dermatitis Using Upadacitinib and Dupilumab in Poland

Strachota S., Książek P., Dziadek K., Pruszko C.
Open
Other publications